Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Albano L et al. | OSAKA trial: a randomized, controlled trial comparing tacrolimus QD and BD in kidney transplantation. | 2013 | Transplantation | pmid:23982340 |
Marcos A et al. | Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. | 2004 | Transplantation | pmid:15480160 |
Suzuki H et al. | Induction of transplantation tolerance in adult rats by vascularized spleen transplantation. | 1997 | Transplantation | pmid:9293881 |
First MR and Fitzsimmons WE | New drugs to improve transplant outcomes. | 2004 | Transplantation | pmid:15201693 |
Francavilla A et al. | Inhibition of liver, kidney, and intestine regeneration by rapamycin. | 1992 | Transplantation | pmid:1371198 |
Sheikh AM et al. | Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels. | 1999 | Transplantation | pmid:10440408 |
Moxey-Mims MM | Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506) | 1999 | Transplantation | pmid:10440413 |
Guethoff S et al. | Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine a in combination with mycophenolate mofetil after heart transplantation. | 2013 | Transplantation | pmid:23423270 |
Naesens M et al. | The impact of renal allograft function on exposure and elimination of mycophenolic acid (MPA) and its metabolite MPA 7-O-glucuronide. | 2007 | Transplantation | pmid:17700162 |
Pratschke J et al. | Treatment of cyclosporine-related adverse effects by conversion to tacrolimus after liver transplantation. | 1997 | Transplantation | pmid:9326428 |
McGhee B et al. | Therapeutic use of an extemporaneously prepared oral suspension of tacrolimus in pediatric patients. | 1997 | Transplantation | pmid:9326429 |
Huang E et al. | Alemtuzumab induction in deceased donor kidney transplantation. | 2007 | Transplantation | pmid:17984833 |
High KP | The antimicrobial activities of cyclosporine, FK506, and rapamycin. | 1994 | Transplantation | pmid:7517076 |
Yoshimura N et al. | The direct effect of FK506 and rapamycin on interleukin 1(beta) and immunoglobulin production in vitro. | 1994 | Transplantation | pmid:7517078 |
Tze WJ et al. | In vitro effects of FK-506 on human and rat islets. | 1990 | Transplantation | pmid:1694319 |
Kahan BD | An immunosuppressive triumvirate to minimize renal injuries associated with calcineurin antagonist therapy. | 1999 | Transplantation | pmid:10428260 |
Washburn K et al. | Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil. | 2001 | Transplantation | pmid:11726831 |
Muthukumar T et al. | HIV-infected kidney graft recipients managed with an early corticosteroid withdrawal protocol: clinical outcomes and messenger RNA profiles. | 2013 | Transplantation | pmid:23503504 |
Moxey-Mims MM et al. | Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506) | 1998 | Transplantation | pmid:9521193 |
Hytiroglou P et al. | FK506 versus cyclosporine as primary immunosuppressive agent for orthotopic liver allograft recipients. Histologic and immunopathologic observations. | 1993 | Transplantation | pmid:7506452 |
Murase N et al. | FK506 suppression of heart and liver allograft rejection. II: The induction of graft acceptance in rats. | 1990 | Transplantation | pmid:1700504 |
Shapiro R et al. | Pediatric renal transplantation under tacrolimus-based immunosuppression. | 1999 | Transplantation | pmid:10075598 |
Kaplan B et al. | Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient: possible relationship to intestinal P-glycoprotein activity. | 1999 | Transplantation | pmid:10075604 |
Ciancio G et al. | Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplantation with tacrolimus and steroid avoidance: four-year analysis. | 2011 | Transplantation | pmid:21107305 |
Erden E et al. | Plasma FK506 levels in patients with histopathologically documented renal allograft rejection. | 1994 | Transplantation | pmid:7519801 |
Reddy KS et al. | Simultaneous kidney-pancreas transplantation without antilymphocyte induction. | 2000 | Transplantation | pmid:10653379 |
Morikawa K et al. | The distinct effects of FK506 on the activation, proliferation, and differentiation of human B lymphocytes. | 1992 | Transplantation | pmid:1281561 |
Arzouk N et al. | Interaction between tacrolimus and fumagillin in two kidney transplant recipients. | 2006 | Transplantation | pmid:16421493 |
Kandula P et al. | Impact of tacrolimus-sirolimus maintenance immunosuppression on proteinuria and kidney function in pancreas transplant alone recipients. | 2012 | Transplantation | pmid:23037007 |
Ciancio G et al. | The use of Campath-1H as induction therapy in renal transplantation: preliminary results. | 2004 | Transplantation | pmid:15316372 |
Berg UB et al. | Renal function before and long after liver transplantation in children. | 2001 | Transplantation | pmid:11544422 |
Murase N et al. | Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs. | 1993 | Transplantation | pmid:7682735 |
Dean PG et al. | Kidney transplant histology after one year of continuous therapy with sirolimus compared with tacrolimus. | 2008 | Transplantation | pmid:18431244 |
Shoji T et al. | Operational tolerance to class I disparate lungs can be induced despite pretransplant immunization with class I allopeptides. | 2007 | Transplantation | pmid:18091523 |
Woodle ES et al. | Tacrolimus therapy for refractory acute renal allograft rejection: definition of the histologic response by protocol biopsies. | 1996 | Transplantation | pmid:8878382 |
McLaren A | Tacrolimus pharmacogenetics: bringing the laboratory into the clinic. | 2003 | Transplantation | pmid:14705621 |
Tanaka A et al. | Living related liver transplantation across ABO blood groups. | 1994 | Transplantation | pmid:7522363 |
Roberts CA et al. | Asymmetric cardiac hypertrophy at autopsy in patients who received FK506 (tacrolimus) or cyclosporine A after liver transplant. | 2002 | Transplantation | pmid:12364862 |
Vincenti F et al. | A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. | 2002 | Transplantation | pmid:11907427 |
Nguyen L et al. | Conversion from tacrolimus/mycophenolic acid to tacrolimus/leflunomide to treat cutaneous warts in a series of four pediatric renal allograft recipients. | 2012 | Transplantation | pmid:22960763 |
Thomas PG et al. | Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. | 2007 | Transplantation | pmid:17565326 |
Dhar DK et al. | The salutary effect of FK506 in ischemia-reperfusion injury of the canine liver. | 1992 | Transplantation | pmid:1384188 |
Bashuda H et al. | Induction of persistent allograft tolerance in the rat by combined treatment with anti-leukocyte function-associated antigen-1 and anti-intercellular adhesion molecule-1 monoclonal antibodies, donor-specific transfusion, and FK506. | 1996 | Transplantation | pmid:8693525 |
Hu H et al. | Effect of immunosuppressants on T-cell subsets observed in vivo using carboxy-fluorescein diacetate succinimidyl ester labeling. | 2003 | Transplantation | pmid:12698107 |
Fredericks S and Holt DW | TGF-beta quantitation can be tricky. | 1999 | Transplantation | pmid:10480399 |
Gruessner RW et al. | Over 500 solitary pancreas transplants in nonuremic patients with brittle diabetes mellitus. | 2008 | Transplantation | pmid:18192910 |
Holman MJ et al. | FK506-associated thrombotic thrombocytopenic purpura. | 1993 | Transplantation | pmid:7678357 |
Todo S et al. | Small intestinal transplantation in humans with or without the colon. | 1994 | Transplantation | pmid:7512291 |
Griffith BP et al. | A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation. | 1994 | Transplantation | pmid:7512292 |
Sun S et al. | Effect of tacrolimus on hemodynamics and absorption of experimental small intestinal transplants. | 1996 | Transplantation | pmid:8633368 |